Transdermal contraceptive patches: Development, clinical performance, and future prospects

American Journal of Drug Delivery

Volumn 4, Issue 4, 2006, Pages 201-213

  Lin, Senshang ^a   Chien, Yie W ^b  

^a ST JOHN'S UNIVERSITY   (United States)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ELCOMETRINE; ESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORGESTIMATE; PLACEBO;

APPLICATION SITE REACTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTRACEPTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DYSMENORRHEA; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TRANSDERMAL PATCH; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33847214966     PISSN: 11759038     EISSN: None     Source Type: Journal    
DOI: 10.2165/00137696-200604040-00003     Document Type: Review

References (76)

1. Sitruk-Ware R. Contraception: an international perspective. Contraception 2006; 73 (3): 215-22
2. Scholtz D, Carmichael JM. Contraception. In: Herfindal ET, Gourley DR, editors, Textbook of therapeutics: drug and disease management. Philadelphia (PA): Lippincott Williams and Wilkins, 2000: 2019-36
3. Frye CA. An overview of oral contraceptives: mechanism of action and clinical use. Neurology 2006; 66 (6 Suppl. 3): S29-36
4. Bucci KK, Carson DS. Contraception. In: DiPiro JT, Talbert RL, editors, Pharmacotherapy. Stamford (CT): Appleton and Lange, 1997: 1601-20
5. Sitruk-Ware R. Delivery options for contraceptives. Drug Discov Today 2005; 10 (14): 977-85
6. Freeman S. Nondaily hormonal contraception: considerations in contraceptive choice and patient counseling. J Am Acad Nurse Pract 2004; 16 (6): 226-38
7. Johansson ED. Future developments in hormonal contraception. Am J Obstet Gynecol 2004; 190 (4 Suppl.): S69-71
8. Logsdon S, Richards J, Omar HA. Long-term evaluation of the use of the transdermal contraceptive patch in adolescents. ScientificWorldJournal 2004; 4: 512-6
9. Forinash AB, Evans SL. New hormonal contraceptives: a comprehensive review of the literature. Pharmacotherapy 2003; 23 (12): 1573-91
10. Linn ES. Progress in contraception: new technology. Int J Fertil Womens Med 2003; 48 (4): 182-91
11. Pettinato A, Emans SJ. New contraceptive methods: update 2003. Curr Opin Pediatr 2003; 15 (4): 362-9
12. Shulman LP. Advances in female hormonal contraception: current alternatives to oral regimens. Treat Endocrinol 2003; 2 (4): 247-56
13. Grow DR, Ahmed S. New contraceptive methods. Obstet Gynecol Clin North Am 2000; 27 (4): 901-16
14. Benson H, Gordon L, Mitchell C, et al. Patient education and intrauterine contra ception: a study of two package inserts. Am J Public Health 1977; 67 (5): 446-9
15. Newton J, Szontagh F, Lebech P, et al. A collaborative study of the progesterone intrauterine device (Progestasert). The World Health Organization Task Force on Methods for the Regulation of Implantation. Contraception 1979; 19 (6): 575-89
16. Ylostalo P, Rantakyla P, Jarvinen PA, et al. Intrauterine progesterone contraceptive system as an alternative in cases where conventional IUDs are unsuitable. Acta Obstet Gynecol Scand 1979; 58 (3): 279-81
17. Wan LS. Clinical experience with Progestasert beyond one year of use. Contracept Deliv Syst 1981; 2 (3): 243-8
18. Fotherby K, Koetsawang S, Mathrubutham M. Pharmacokinetic study of different doses of Depo Provera. Contraception 1980; 22 (5): 527-36
19. Mukherjea M, Mukherjee P, Biswas R. Long-term contraception with Depo-Provera: a clinical evaluation. Int J Fertil 1980; 25 (2): 122-6
20. Jarman H, Kovacs GT, Westcott M. Depo Provera: a profile of current users. Aust N Z J Obstet Gynaecol 1990; 30 (1): 74-6
21. Bigrigg A, Evans M, Gbolade B, et al. Depo Provera: position paper on clinical use, effectiveness and side effects. Br J Fam Plann 1999; 25 (2): 69-76
22. Wehrle KE. The Norplant system: easy to insert, easy to remove. Nurse Pract 1994; 19 (4): 47-54
23. Fraser IS, Tiitinen A, Affandi B, et al. Norplant consensus statement and background review. Contraception 1998; 57 (1): 1-9
24. Coukell AJ, Balfour JA. Levonorgestrel subdermal implants: a review of contraceptive efficacy and acceptability. Drugs 1998; 55 (6): 861-87
25. Baldaszti E, Wimmer-Puchinger B, Loschke K. Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study. Contraception 2003; 67 (2): 87-91
26. McGavigan CJ, Cameron IT. The Mirena levonorgestrel system. Drugs Today (Barc) 2003; 39 (12): 973-84
27. Dubuisson JB, Mugnier E. Acceptability of the levonorgestrel-releasing intrauterine system after discontinuation of previous contraception: results of a French clinical study in women aged 35 to 45 years. Contraception 2002; 66 (2): 121-8
28. Rahimy MH, Ryan KK, Hopkins NK. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women. Contraception 1999; 60 (4): 209-14
29. Rahimy MH, Ryan KK. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women. Contraception 1999; 60 (4): 189-200
30. Rahimy MH, Cromie MA, Hopkins NK, et al. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): effects of body weight and injection sites on pharmacokinetics. Contraception 1999; 60 (4): 201-8
31. Shulman LP, Oleen-Burkey M, Willke RJ. Patient acceptability and satisfaction with Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension). Contraception 1999; 60 (4): 215-22
32. Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000; 39 (3): 233-42
33. Mulders TM, Dieben TO. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril 2001; 75 (5): 865-70
34. Szarewski A. High acceptability and satisfaction with NuvaRing use. Eur J Contracept Reprod Health Care 2002; 7 Suppl. 2: 31-6
35. Roumen F. Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing. Eur J Contracept Reprod Health Care 2002; 7 Suppl. 2: 19-24
36. Mulders TM, Dieben TO, Bennink HJ. Ovarian function with a novel combined contraceptive vaginal ring. Hum Reprod 2002; 17 (10): 2594-9
37. Burkman RT. The transdermal contraceptive system. Am J Obstet Gynecol 2004; 190 (4 Suppl.): S49-53
38. Sicat BL. Ortho Evra, a new contraceptive patch. Pharmacotherapy 2003; 23 (4): 472-80
39. Creasy GW, Abrams LS, Fisher AC. Transdermal contraception. Semin Reprod Med 2001; 19 (4): 373-80
40. Goa KL, Warner GT, Easthope SE. Transdermal ethinylestradiol/ norelgestromin: a review of its use in hormonal contraception. Treat Endocrinol 2003; 2 (3): 191-206
41. Calderoni ME, Coupey SM. Combined hormonal contraception. Adolesc Med Clin 2005; 16 (3): 517-37
42. Potts RO, Lobo RA. Transdermal drug delivery: clinical considerations for the obstetrician-gynecologist. Obstet Gynecol 2005; 105 (5 Pt 1): 953-61
43. Henzl MR, Loomba PK. Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice. J Reprod Med 2003; 48 (7): 525-40
44. Sitruk-Ware R. Transdermal application of steroid hormones for contraception. J Steroid Biochem Mol Biol 1995; 53 (1-6): 247-51
45. Ortho Evra (norelgestromin/ethinyl estradiol transdermal system) prescribing information [online]. Available from URL: http://www.orthoevra.com/ active/janus/en_US/assets/common/company/pi/orthoevra.pdf#zoom=100 [Accessed 2006 Jun 15]
46. Chien YW, Lin S. Optimisation of treatment by applying programmable rate-controlled drug delivery technology. Clin Pharmacokinet 2002; 41 (15): 1267-99
47. Abrams LS, Skee DM, Natarajan J, et al. Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites. Br J Clin Pharmacol 2002; 53 (2): 141-6
48. Abrams LS, Skee D, Natarajan J, et al. Pharmacokinetic overview of Ortho Evra/Evra. Fertil Steril 2002; 77 (2 Suppl. 2): S3-12
49. Abrams LS, Skee DM, Wong FA, et al. Pharmacokinetics of norelgestromin and ethinyl estradiol from two consecutive contraceptive patches. J Clin Pharmacol 2001; 41 (11): 1232-7
50. Zacur HA, Hedon B, Mansour D, et al. Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertil Steril 2002; 77 (2 Suppl. 2): S32-5
51. Abrams LS, Skee DM, Natarajan J, et al. Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise. J Clin Pharmacol 2001; 41 (12): 1301-9
52. Abrams LS, Skee DM, Natarajan J, et al. Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants. Contraception 2001; 64 (5): 287-94
53. Dittrich R, Parker L, Rosen JB, et al. Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study. Am J Obstet Gynecol 2002; 186 (1): 15-20
54. Urdl W, Apter D, Alperstein A, et al. Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception. Eur J Obstet Gynecol Reprod Biol 2005; 121 (2): 202-10
55. Pierson RA, Archer DF, Moreau M, et al. Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Fertil Steril 2003; 80 (1): 34-42
56. Burkman RT. The transdermal contraceptive patch: a new approach to hormonal contraception. Int J Fertil Womens Med 2002; 47 (2): 69-76
57. Sibai BM, Odlind V, Meador ML, et al. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Fertil Steril 2002; 77 (2 Suppl. 2): S19-26
58. Smallwood GH, Meador ML, Lenihan JP, et al. Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol 2001; 98 (5 Pt 1): 799-805
59. Zieman M, Guillebaud J, Weisberg E, et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002; 77 (2 Suppl. 2): S13-8
60. Audet MC, Moreau M, Koltun WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001; 285 (18): 2347-54
61. Archer DF, Bigrigg A, Smallwood GH, et al. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. Fertil Steril 2002; 77 (2 Suppl. 2): S27-31
62. Archer DF, Cullins V, Creasy GW, et al. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy. Contraception 2004; 69 (3): 189-95
63. Weisberg F, Bouchard C, Moreau M, et al. Preference for and satisfaction of Canadian women with the transdermal contraceptive patch versus previous contraceptive method: an open-label, multicentre study. J Obstet Gynaecol Can 2005; 27 (4): 350-9
64. Creasy GW, Fisher AC, Hall N, et al. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile. J Reprod Med 2003; 48 (3): 179-86
65. Friend DR. Transdermal delivery of contraceptives. Crit Rev Ther Drug Carrier Syst 1990; 7 (2): 149-86
66. Vora B, Khopade AJ, Jain NK. Proniosome based transdermal delivery of levonorgestrel for effective contraception. J Control Release 1998; 54 (2): 149-65
67. Friend DR, Catz P, Heller J, et al. Transdermal delivery of levonorgestrel. IV: Evaluation of membranes. J Pharm Sci 1989; 78 (6): 477-80
68. Friend DR, Catz P, Heller J, et al. Transdermal delivery of levonorgestrel. V. Preparation of devices and evaluation in vitro. Pharm Res 1989; 6 (11): 938-44
69. Chien YW, Chien TY, Huang YC. Transdermal fertility control system and process (U.S. Patent #5,296,230), 22 Mar 1994
70. Chien TY, Wu SJ, Gong SJ, et al. Transdermal contraceptive delivery system: preclinical development and clinical assessment. Drug Develop & Industrial Pharm 1994; 20 (4): 633-64
71. Croxatto HB, Zepeda A. Transdermal contraceptive systems: innovative technology for the twenty-first century. In: Sitruk-Ware R, Bardin W, editors, Contraception. Newer Pharmacological Agents, Devices, and Delivery Systems. New York: Marcel Dekker, Inc., 1992: 101-15
72. Heger-Mahn D, Warlimont C, Faustmann T, et al. Combined ethinylestradiol/gestodene contraceptive patch: two-center, open-label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers. Eur J Contracept Reprod Health Care 2004; 9 (3): 173-81
73. Chien YW, Lambert HJ. Microsealed pharmaceutical delivery device (U.S. Patent 3,992,518), 16 Nov 1976
74. Chien YW, Lambert HJ. Microsealed pharmaceutical delivery device. (U.S. Patent 4,053,580), 11 Oct 1977
75. Chien YW. Novel drug delivery systems: 2nd ed. Rev. Exp. New York: Marcel Dekker, Inc., 1992: 808
76. Sitruk-Ware R, Small M, Kumar N, et al. Nestorone: clinical applications for contraception and HRT. Steroids 2003; 68 (10-13): 907-13